Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 28, 2016; 22(8): 2424-2433
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2424
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2424
Table 1 Initial reconstruction, interval, and location of remnant gastric cancer based on primary disease
Ref. | Primary disease | No. of patients | Initial reconstruction (B-I/B-II/R-Y) | Interval (yr) | Location (Stomal/non-stomal) |
Tanigawa et al[8] 2002 | Benign | 20 | 7/13 | 25.8 | 8/12 |
Cancer | 27 | 18/9 | 10.6 | 3/24 | |
An et al[22] 2007 | Benign | 25 | - | 28.6 | 16/9 |
Cancer | 13 | - | 18.8 | 7/6 | |
Ohashi et al[23] 2007 | Cancer | 108 | 71/281 | 7.5 | 14/94 |
Schaefer et al[24] 2007 | Benign | 19 | 1/18 | 34.0 | 11/8 |
Ahn et al[25] 2008 | Benign | 13 | 0/13 | 32.4 | 12/1 |
Cancer | 45 | 6/381 | 6.8 | 23/21 | |
Firat et al[26] 2009 | Benign | 26 | 0/26 | 32.0 | 16/10 |
Ojima et al[27] 2010 | Benign | 17 | 12/5 | 22.0 | 8/9 |
Cancer | 21 | 16/5 | 9.0 | 2/19 | |
Mezhir et al[3] 2011 | Benign | 105 | B-II: 97 | 32.0 | 72/33 |
Komatsu et al[28] 2012 | Benign | 19 | 4/15 | 30.0 | 9/10 |
Cancer | 14 | 12/11 | 12.0 | 2/12 | |
Li et al[29] 2013 | Benign | 88 | 28/60 | 32.1 | 55/33 |
Cancer | 24 | 14/10 | 16.8 | 9/15 | |
Tokunaga et al[30] 2013 | Benign | 89 | 23/66 | 31.0 | 46/43 |
Cancer | 78 | 59/171 | 9.4 | 13/65 | |
Leo et al[31] 2014 | Benign | 176 | 10/167 | 34.6 | 71/105 |
Table 2 The success rate of Helicobacter pylori eradication therapy in remnant stomach
Ref. | No. of patients | Regimen of eradication | Success rate, n (%) |
Matsukura et al[42] 2003 | 20 | Dual therapy | 14 (70.0) |
Lansoprazole 60 mg, AMPC 1500 mg for 2 wk | |||
20 | Triple therapy | 18 (90.0) | |
Lansoprazole 60 mg, AMPC 1500 mg, CAM 800 mg daily for 1 wk | |||
Onoda et al[52] 2005 | 33 | Triple therapy | 30 (90.9) |
Rabeprazole 20 mg, AMPC 1500 mg, CAM 800 mg daily for 1 wk | |||
Kim et al[53] 2008 | 61 | Triple therapy | 53 (86.9) |
Rabeprazole 20 mg, AMPC 2000 mg, CAM 1000 mg daily for 1 wk |
Table 3 The incidence of lymph node metastases of remnant gastric cancer and primary proximal gastric cancer in the splenic hilar region, around the splenic artery, in the lower mediastinum, and in the jejunal mesentery
Ref. | No. of patients | Splenic hilar(No. 10) | Splenic artery(No. 11) | Lower mediastinum | Jejunal mesentery lymph node metastases | ||
No. 110 | No. 111 | ||||||
Sasako et al[59] 1991 | RGC | 52 | 15.2% | 23.5% | - | - | 15.2% |
PPGC | 656 | 10.4% | 10.4% | - | - | - | |
Ikeguchi et al[60] 1994 | RGC | 20 | 0% | 25.0% | - | - | 10.0% |
PPGC | 266 | 11.3% | 15.4% | - | - | - | |
Thorban et al[57] 2000 | RGC | 47 | - | - | - | - | 31.9% |
PPGC | 498 | - | - | - | - | - | |
Tanigawa et al[8] 2002 | RGC | 32 | 8.3% | 9.1% | - | 50.0% | 60.0% |
PPGC | 310 | 16.7% | 21.7% | - | 6.7% | - | |
Han et al[61] 2003 | RGC | 67 | 60.0% | 72.3% | - | 50.0% | 16.7% |
PPGC | - | - | - | - | - | - | |
Schaefer et al[24] 2007 | RGC | 19 | - | - | - | - | 22.2% |
PPGC | 194 | - | - | - | - | - | |
Li et al[62] 2012 | RGC | 83 | 21.4% | 14.2% | 33.3% | 33.3% | 54.5% |
PPGC | 300 | 36.4% | 16.7% | 13.6% | 13.0% | - | |
Komatsu et al[63] 2012 | RGC | 33 | 12.1% | - | - | - | 67.0% |
PPGC | 207 | 6.8% | - | - | - | - | |
Leo et al[31] 2014 | RGC | 176 | 10.0% | 7.1% | - | - | 46.4% |
PPGC | - | - | - | - | - | - |
Table 4 Comparison of operative outcomes between remnant gastric cancer and primary proximal gastric cancer
Ref. | No. of patients | R0 resection rate (%) | Adjacent organ resection rate | Prognosis after curative resection | |
Thorban et al[57] 2000 | RGC | 50 | 85.1 | Colon: 19.1%, pancreas: 6.4%, liver: 8.5% | MST: 30.9 mo |
PPGC | 516 | 73.9 | Colon: 0%, pancreas: 2.8%, liver: 4.9% | MST: 32.1 mo | |
Tanigawa et al[8] 2002 | RGC | 47 | 68.1 | 68.1% | 5-yr OS: 56% |
PPGC | 310 | - | - | 5-yr OS: 53% | |
An et al[22] 2007 | RGC | 38 | 92.1 | - | 5-yr OS: 54% |
PPGC | 794 | 86.4 | - | 5-yr OS: 63% | |
Schaefer et al[24] 2007 | RGC | 19 | - | Colon: 5.3%, pancreas: 10.5%, liver: 5.3% | 5-yr OS: 71% |
PPGC | 194 | - | - | 5-yr OS: 48% | |
Mezhir et al[3] 2011 | RGC | 105 | 60.0 | Colon: 10.1%, pancreas or liver: 5.8% | 5-yr OS: 53% |
PPGC | 2099 | - | - | Unknown | |
Komatsu et al[63] 2012 | RGC | 33 | 78.8 | Colon: 6.1%, pancreas: 12.2%, liver: 6.1% | Unknown |
PPGC | 207 | - | Colon: 2.9%, pancreas: 4.3%, liver: 1.9% | Unknown | |
Tokunaga et al[30] 2013 | RGC | 167 | 88.0 | - | 5-yr OS: 54% |
PPGC | 755 | 93.8 | - | 5-yr OS: 78% |
Table 5 Clinical outcomes of endoscopic submucosal dissection for remnant gastric cancer n (%)
Ref. | No. of ESD lesions | No. of lesions located on the suture line | En bloc resection rate | Complete resection rate | Complications | |
Perforation | Bleeding | |||||
Takenaka et al[65] 2008 | 31 | 12 (38.7) | 30 (96.8) | 23 (74.2) | 4 (12.9) | 0 |
Hirasaki et al[66] 2008 | 17 | - | 17 (100) | 14 (82.4) | 0 | 3 (17.6) |
Hoteya et al[67] 2010 | 401 | - | - | 38 (95.0) | 1 (2.5) | 2 (5.0) |
Lee et al[68] 2010 | 13 | 6 (46.2) | 13 (100) | 11 (84.6) | 0 | 0 |
Nishide et al[69] 2012 | 622 | 29 (46.8) | 59 (95.2) | 53 (85.5) | 11 (17.7) | 5 (8.2) |
Nonaka et al[70] 2013 | 94 | - | 86 (91.5) | 77 (81.9) | 2 (2.1) | 2 (2.1) |
Tanaka et al[71] 2014 | 33 | 11 (33.3) | 33 (100) | 31 (93.9) | 3 (9.1) | 1 (3.0) |
Table 6 Clinical outcomes of laparoscopic surgery for remnant gastric cancer
Ref. | Type of procedure | No. of patients | Operation time (min) | Blood loss (mL) | Conversion to open surgery | No. of retrieved lymph nodes | Complication rate (%) | 5-yr OS (%) |
Kim et al[76] 2014 | Lap | 171 | 197 | - | 0% | 12.9 | 23.5 | - |
Open | 50 | 149 | - | - | - | 30.0 | - | |
Kwon et al[77] 2014 | Lap | 182 | 266 | 182 | 5.6% | 8 | 33.3 | 100.0 |
Open | 58 | 203 | 193 | - | 7 | 44.8 | 94.9 | |
Nagai et al[78] 2014 | Lap | 12 | 362 | 69 | 0% | 23.7 | 0.0 | 77.8 |
Open | 10 | 271 | 746 | - | 15.9 | 20.0 | 72.9 | |
Tsunoda et al[79] 2014 | Lap | 10 | 325 | 55 | 0% | 22 | 10.0 | - |
Open | 6 | 289 | 893 | - | 7 | 33.3 | - | |
Son et al[80] 2015 | Lap | 17 | 234 | 228 | 47.1% | 18.8 | 35.3 | 67.0 |
Open | 17 | 170 | 184 | - | 22.3 | 29.4 | 60.3 |
- Citation: Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, Yashiro M, Onoda N, Hirakawa K. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol 2016; 22(8): 2424-2433
- URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2424.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i8.2424